ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharmaceuticals Business	58.93B	56.66B	56.02B	53.58B	50.79B
Pharmaceuticals Business Growth	4.01%	1.14%	4.55%	5.49%	-
Animal Health Business	7.33B	7.25B	6.66B	6.66B	-
Animal Health Business Growth	1.21%	8.73%	0.06%	-	-
Overseas Business	4.64B	-	-	-	-
Other	306.00M	325.00M	226.00M	298.00M	5.89B
Other Growth	-5.85%	43.81%	-24.16%	-94.94%	-
Unallocated Adjustment	-81.00M	-88.00M	-64.00M	-77.00M	-73.00M
Total	71.13B	64.14B	62.84B	60.46B	56.61B
Total Growth	10.90%	2.06%	3.94%	6.80%	-

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Japan	71.13B	64.14B	62.84B	60.46B	56.61B
Japan Growth	10.90%	2.06%	3.94%	6.81%	-
Total	71.13B	64.14B	62.84B	60.46B	56.61B
Total Growth	10.90%	2.06%	3.94%	6.81%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 15, 2026

Data Sources Report a data error